The FDA has granted a third approval for WELIREG, authorizing its use as a treatment for patients with rare endocrine system tumors known as pheochromocytoma or paraganglioma (PPGL). This approval applies to individuals aged 12 and older with locally advanced, unresectable, or metastatic...
Read More Details
Finally We wish PressBee provided you with enough information of ( Merck's WELIREG Entry Brings New Momentum to Pheochromocytomas and Paragangliomas Therapeutics Market .. DelveInsight )
Also on site :
- Chipotle is Giving Away Free Burritos for An Entire Year—Here's How to Win
- 19 Sex Scenes on ‘The White Lotus,’ From Absolutely Awkward to Incredibly Hot
- Is Ashley Leaving 'The Young and the Restless'?